Search Results

In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage.

Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.

NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.

Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.

Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.

Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs.